Burghardt E, Lahousen M, Stettner H
Baillieres Clin Obstet Gynaecol. 1989 Mar;3(1):157-65. doi: 10.1016/s0950-3552(89)80050-1.
Since 1980, 95 of 320 patients with ovarian cancer of Stages I to IV have undergone pelvic lymphadenectomy. A further 57 patients underwent pelvic and para-aortic lymphadenectomy. In the last three years, 83% of patients with Stage III disease had a lymphadenectomy, and 34% had no gross residual tumour after surgery. This entailed bowel resection in 33% of cases. After cytoreduction and chemotherapy, actuarial 5-year survival in Stages I and II was 90%, and was just over 40% in Stage III. Patients with positive nodes had markedly poorer survival than did those with negative nodes. Three years after only pelvic lymphadenectomy, 36.7% of patients with Stage III disease had no clinical, radiological or biochemical evidence of disease. If the abdomen had been cleared of gross disease at surgery, 70% of the patients had no evidence of disease at 3 years. The therapeutic effect of lymphadenectomy is also reflected in the marked improvement in survival of all patients with Stage III ovarian cancer after the introduction of lymphadenectomy.
自1980年以来，320例I至IV期卵巢癌患者中有95例接受了盆腔淋巴结清扫术。另有57例患者接受了盆腔及腹主动脉旁淋巴结清扫术。在过去三年中，83%的III期疾病患者接受了淋巴结清扫术，34%的患者术后无肉眼可见的残留肿瘤。这在33%的病例中需要进行肠切除。在肿瘤细胞减灭术和化疗后，I期和II期患者的精算5年生存率为90%，III期患者略高于40%。有阳性淋巴结的患者生存率明显低于有阴性淋巴结的患者。仅行盆腔淋巴结清扫术三年后，36.7%的III期疾病患者无疾病的临床、影像学或生化证据。如果手术时腹部已清除肉眼可见的疾病，70%的患者在三年时无疾病证据。淋巴结清扫术的治疗效果还体现在引入淋巴结清扫术后所有III期卵巢癌患者生存率的显著提高。
